By VETTAPHARMA reporter – Derek Roche: U.S. Food and Drug Administration approved Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) for adult patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC). The approval was supported by results from the POTOMAC trial (NCT03528694), which evaluated durvalumab in combination with BCG induction and maintenance therapy compared with BCG alone in patients with high-risk NMIBC.
The study demonstrated a statistically significant improvement in disease-free survival, reducing the risk of disease recurrence, progression, or death compared with BCG alone. The trial reported a hazard ratio of 0.68 (95% CI: 0.50–0.93; p=0.0154). Median disease-free survival had not been reached in either treatment arm at the time of analysis.
Patients in the durvalumab treatment arm received 1500 mg every four weeks for up to 13 cycles alongside BCG induction and maintenance therapy.
High-risk NMIBC remains associated with substantial risk of recurrence and progression despite standard intravesical therapy, making durable disease control a major treatment objective in this setting.
The approval expands the use of immunotherapy into earlier-stage bladder cancer management and reflects continued focus on improving outcomes before progression to muscle-invasive disease.
For patients with high-risk NMIBC, the approval introduces an additional treatment option that may improve disease-free survival and help delay recurrence or progression.
From a commercial perspective, the approval broadens the clinical footprint of Imfinzi within bladder cancer and supports continued expansion of immunotherapy use across earlier-stage oncology settings.
Quick FAQs
1. What is high-risk non-muscle-invasive bladder cancer (NMIBC)?
High-risk NMIBC is a form of bladder cancer confined to the bladder lining but associated with a significant risk of recurrence and progression to more advanced disease.
2. What is the POTOMAC study?
POTOMAC (NCT03528694) is a clinical trial evaluating Imfinzi (durvalumab) in combination with BCG versus BCG alone in patients with BCG-naïve high-risk NMIBC.
3. What is Imfinzi (durvalumab)?
Imfinzi is an immunotherapy that targets PD-L1 and is designed to enhance immune responses against cancer cells.
4. What were the key findings from the POTOMAC trial?
The study demonstrated a statistically significant improvement in disease-free survival with durvalumab plus BCG compared with BCG alone.
5. Why is this FDA approval important?
The approval introduces an immunotherapy-based treatment approach for patients with high-risk NMIBC.
6. What could this mean for patients?
The combination may improve long-term disease control and help delay disease recurrence or progression.
